Management of cerebral azole-resistant Aspergillus fumigatus infection: A role for intraventricular liposomal-amphotericin B

A. F.A.D. Schauwvlieghe, R. G.M. Bredius, R. M. Verdijk, F. J.W. Smiers, M. T. van der Beek, B. F. Goemans, C. M. Zwaan, R. J. Brüggemann, B. J.A. Rijnders

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

5 Citaten (Scopus)

Samenvatting

Objectives: In the pre-azole era, central nervous system (CNS) infections with Aspergillus had a dismal outcome. Survival improved with voriconazole but CNS infections caused by azole-resistant Aspergillus fumigatus preclude its use. Intravenous liposomal-amphotericin B (L-AmB) is the preferred treatment option for azole-resistant CNS infections but has suboptimal brain concentrations. Methods: We describe three patients with biopsy-proven CNS aspergillosis where intraventricular L-AmB was added to systemic therapy. Two patients with azole-resistant aspergillosis and one patient with azole-susceptible CNS aspergillosis were treated with intraventricular L-AmB at a dose of 1 mg weekly. Results: We describe three patients successfully treated with a combination of intravenous and intraventricular L-AmB. All three patients survived but one patient developed serious headaches, most likely not related to this treatment. Conclusions: Intraventricular L-AmB may have a role in the treatment of therapy-refractory CNS aspergillosis when added to systemic therapy.

Originele taal-2Engels
Pagina's (van-tot)354-357
Aantal pagina's4
TijdschriftJournal of Global Antimicrobial Resistance
Volume22
DOI's
StatusGepubliceerd - sep. 2020

Vingerafdruk

Duik in de onderzoeksthema's van 'Management of cerebral azole-resistant Aspergillus fumigatus infection: A role for intraventricular liposomal-amphotericin B'. Samen vormen ze een unieke vingerafdruk.

Citeer dit